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a  b  s  t  r  a  c  t
The  constant  supply  of  high  cell  numbers  generated  by  deﬁned,  robust,  and  economically  viable  culture
processes  is indispensable  for  the envisioned  application  of  human  pluripotent  stem  cells  (hPSCs)  and
their  progenies  for drug  discovery  and  regenerative  medicine.  To achieve  required  cell  numbers  and  to
reduce process-related  risks  such  as  cell  transformation,  relative  short  batch-like  production  processes
at  industry-  and  clinically-relevant  scale(s)  must  be  developed  and  optimized.  Here, we will review
recent  progress  in  the  large-scale  expansion  of  hPSCs  with  particular  focus  on  suspension  culture,  which
represents  a  universal  strategy  for controlled  mass  cell production.  Another  focus  of  the paper  relates
to  bioreactor-based  approaches,  including  technical  aspects  of bioreactor  technologies  and  operation
modes.  Lastly,  we will  discuss  current  challenges  of hPSC  process  engineering  for enabling  the transition
from  early  stage  process  development  to  fully  optimized  hPSC  production  scale  operation,  a mandatory
step  for  hPSCs’  industrial  and  clinical  translation.
©  2017  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
1.1. The need for large-scale production of human pluripotent
stem cells and their progenies
Human pluripotent stem cells (hPSCs), including human embry-
onic (hESCs) and induced pluripotent (hiPSCs) stem cells, represent
a unique cell source for the, in principle, unlimited production of
functional human cell types in vitro. In this regard, hPSCs hold great
promise for revolutionizing drug discovery, drug safety assays, in
vitro disease modeling, and ultimately cell-based therapies (Fig. 1)
[1,2].
The evolutionary conservation of mammalian genomes has
resulted in numerous drugs that were discovered by assays
employing ubiquitous cell lines and further validated in typi-
cal rodent models to lack efﬁciency or cause detrimental side
effects after clinical translation [3,4]. Systematic research indeed
revealed limitations of animal models regarding their predictabil-
ity of drug function and toxicity in man. Underlying reasons include
substantial species-speciﬁc differences in (i) cell and tissue phys-
iology (such as liver metabolism, beating rate of the heart, etc.),
(ii) inﬂammatory response, (iii) structure and speciﬁcity of the
immunological system, and (iv) others [5]. This underscores the
necessity for using human cells, ideally tissue-speciﬁc cells, for drug
discovery, validation, and safety pharmacology [1,6,7].
Moreover, for many sporadic and rare diseases caused by genetic
mutations, such as cystic ﬁbrosis [8], hereditary pulmonary alveo-
lar proteinosis (hPAP) [9], or Huntington’s disease [10], novel drug
candidates should ideally be screened and validated in human cells
carrying the respective mutation(s). In contrast to immortalized
cell lines, which are typically used for high throughput screening
(HTS) drug discovery assays, this deems straightforward by using
disease-speciﬁc in vitro models based on patient-derived hiPSC
lines differentiated into functional cell types relevant to the respec-
tive disorder [8].
Beyond drug discovery and disease modeling in vitro, ﬁrst
patients have recently received hPSC progenies aiming for novel
approaches in regenerative medicine. For treating age-related mac-
ular degeneration in the eye, both hESC- [11] and hiPSC-derived
[12] retinal pigment epithelial cells were readily applied. The
implantation of hESC-derived insulin-producing cells in patients
with type 1 diabetes was announced by the company ViaCyte, and
early hESC progenies were readily transplanted to the left ventri-
cle of a ﬁrst heart failure patient via a tissue engineering approach
[13,14].
At present, functional hPSC progenies are mainly generated
by protocols in laboratory scale and quality. However, the envi-
sioned routine application of these cells will require appropriate
large-scale production processes, ultimately by standardized and
economically viable procedures and technologies.
Rough estimations suggest that for replacing disease-induced
loss of hepatocytes, pancreatic -cells, or cardiomyocytes, approx-
imately 1–10 × 109 functional cells per patient will be required.
Even higher needs were calculated for the visionary production of
“in vitro blood”, since approximately 2.5 × 1012 red blood cells are
required per patient in transfusion medicine [15].
It is worth noting that equivalent cell numbers are readily
required ahead of treating patients; for example, for pre-clinical
studies in large animals such as pigs or non-human primates, which
represent more physiologically and functionally relevant models of
human diseases such as heart failure compared to rodents [16–18].
The need for developing well-deﬁned large-scale hPSC expan-
sion and differentiation processes is not dictated by cell number
requirements alone. Another impelling necessity is to comply with
the currently evolving regulatory framework for hPSC-derived
therapeutics, including the application of relevant “current good
manufacturing practice” (cGMP) guidelines [2,19,20].
Taken together, many of the envisioned clinical and indus-
trial applications of hPSCs will depend on the constant, controlled
production of billions of cells. In principle, bioprocesses for the
production of recombinant proteins by common mammalian cell
lines, which have been established in >1000 L scale, may serve as
a blueprint [2,16,18,21]. In this scenario, the established bioreac-
tor systems provide effective technologies to replace laborious and
poorly controlled research-type processes.
By combining process automation, monitoring, and control with
scalability, bioreactor systems are applied to reduce operator-
dependent variability, paving the way  for more robust and
cost-effective hPSC production [22–24].
However, due to their intrinsic potential, hPSCs may  switch from
pluripotency toward (uncontrolled) differentiation not desired
during the cell expansion phase. Moreover, subsequent differenti-
ation into desired lineage(s) is a highly complex process altered by
a multitude of overlapping parameters, which also includes effects
of the proceeding expansion strategy. Therefore, hPSC processing
is substantially more challenging than long-standing strategies for
the cultivation of transformed and relative unpretentious cell lines
typically used in industry and thus requires a high degree of inno-
vation in process development and control [2,16,18,21,25].
2. Culture platforms for hPSC expansion
2.1. 2D culture systems and process scale-out
Undifferentiated hPSCs are conventionally maintained and
expanded at two-dimensional (2D) conditions with cells adher-
ing to the matrix-covered surface of culture plates or ﬂasks. The
cumbersome co-culture of hPSC colonies grown on mitotically inac-
tivated ﬁbroblasts (“feeder cells”) – as initially described for their
routine maintenance [26,27] – has been largely replaced by semi- or
fully-deﬁned matrices such as Matrigel [26], recombinant proteins
(such as laminins [28]), or synthetic polymers [29].
To generate larger cell amounts, scale-out of the 2D approach
has been suggested simply by multiplying culture dishes or by using
multi-layered ﬂasks marketed as “Cell Factories” or “Cell Stacks”
[30]. Thus, the term “scale-out” refers to keeping a manufactur-
ing lot size constant but multiplying the number of parallel unit
operations (see Fig. 2A) [31]. However, although some degree of
process automation for 2D culture has been published [32,33], the
approach remains relatively cost-, space-, and labor-intensive. The
method also restricts the online monitoring and control of key pro-
cess parameters including vital cell counts, dissolved oxygen (DO),
pH, and glucose and growth factor concentrations. It should be
mentioned though that a culture system for large-scale 2D process-
ing of hPSCs based on multilayered plates was recently introduced,
which allows pH and DO monitoring and feedback-based control
[34].
However, 2D cultivation typically relies on static culture con-
ditions known to induce the formation of undesired gradients,
including media components, metabolic waste products, paracrine
factors, and gases. Together, despite its advantageous simplicity,
2D cultivation raises a number of issues that limit the strategies’
utility for the systematic development of hPSC mass production
[24,25,35].
2.2. 3D culture systems and process scale-up
The ﬁeld is recently reaching consensus that three-dimensional
(3D) culture (synonymously termed suspension culture) is a potent
approach to achieve the extensive hPS cell number requirements
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Fig. 1. Possible industrial and clinical applications of human pluripotent stem cells demanding large-scale cell expansion. Human PSCs are derived from the inner cell mass
of  the blastocyst (hESCs) or reprogrammed from the somatic cells (hiPSCs). The expansion and subsequent differentiation of these cells in large-scale culture platforms are
mandatory for reaching the required cell numbers for cell-based therapies, in vitro disease modeling, high content screening for drug discovery, and drug safety assays.
Fig. 2. Expansion strategies for human pluripotent stem cells. The expansion of hPSCs can be performed following two different approaches: (A) Adopting the standard 2D
cultivation methods, i.e.,  the scale-out approach based on increasing the culture surface via increasing the number of cultivation vessels; however, this is cost-, space-, and
labor-intensive; (B) Using 3D cultivation methods within automated bioreactor systems, i.e.,  the scale-up approach based on, e.g., rotating wall bioreactors, wave bioreactors,
shaking  Erlenmeyer ﬂasks, or stirred tank bioreactors depending on the desired ﬁnal cell yield, which allows to increase the overall manufacturing scale. Regarding the
culture strategy within the bioreactors, hPSCs can be cultivated attached to microcarriers or as self-assembling aggregates. Figure adapted from [16].
outlined above [2,36]. While 2D culture is inappropriate to simulate
hPSCs’ “natural microenvironment”, cultivation in suspension cul-
ture based on matrix-free cell-only aggregates (see Section 3.2.1)
may  be a closer match of hES cells’ “in situ niche” i.e.,  equivalent
to the inner cell mass of the early human embryo at the blastocyst
stage [37] from which these cells originate (Fig. 1).
The overall suspension culture environment in combination
with the microenvironment in spherical, multicellular aggregates
seems to support hPSC viability and proliferation at the pluripo-
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tent state while overcoming the necessity of external matrix
supplementation [38,39] (Fig. 2B). Notably, aggregate-based hPSC
cultivation also provides a useful starting point for directly switch-
ing from pluripotency to directed lineage differentiation, which can
be induced and controlled by replacing the respective expansion
media with lineage-speciﬁc differentiation media [40–43].
The use of bioreactor systems facilitates the development
of dynamic suspension cultures, thus overcoming environmen-
tal inhomogeneity typical of static conditions [44,45]. Reactor
type-speciﬁc mixing technologies (i) promote the control of hPSC
aggregation (i.e., after single cell-based process inoculation), (ii)
avoid the formation of gradients by supporting homogeneous dis-
tribution of all culture components, and (iii) improve the mass
transfer of gases and nutrients into cells/aggregates, thereby facil-
itating the development of large-scale hPSC culture processes at
(relative) high cell density [18]. In addition, bioreactor systems are
equipped with technologies for monitoring and (feedback-based)
control of the culture environment, including basic and more spe-
ciﬁc parameters such as temperature, pH, and the concentration of
nutrients (e.g., glucose), metabolites (e.g., lactate, ammonia), and
gases (e.g., O2 and CO2), which substantially facilitate controlled
process up-scaling.
Therefore, in contrast to the scale-out approach, the use of biore-
actor systems allows process “scale-up” deﬁned by the increase in
the overall manufacturing scale [31]. Several types of bioreactor
systems, most of which have been previously developed for cultur-
ing conventional mammalian cell lines, are potentially applicable
to hPSC cultivation and scale-up. In addition to simple Erlenmeyer
ﬂasks, these systems include wave bioreactors (also known as “cell
bags”) and rotating wall, stirred tank, packed bed, hollow ﬁber, bub-
ble column, and airlift bioreactors described in detail elsewhere
[19,22,31,35,39,46–48] (Fig. 2B). Since rotating wall and stirred
tank bioreactors are the most used systems for hPSC production
[18,48,49] (summarized in Table 1), these will be discussed in more
detail.
3. Process engineering for hPSC suspension culture
3.1. Rotating wall bioreactors
In rotating wall bioreactors (RWBs), the cylindrical culture ves-
sel is maintained in continuous rotation along its longitudinal,
horizontal axis, creating a microgravity environment under laminar
ﬂow conditions. The rotation supports mixing and thus homogene-
ity of the overall culture, and, depending on the imposed rotational
speed, a dynamic suspension of the immersed cells/aggregates in
a quasi-periodic circular motion can be achieved. RWBs were ini-
tially used for “embryoid body” (EB)-based differentiation of hESCs
by Gerecht-Nir and coworkers [50]. A 3-fold increase in EB genera-
tion efﬁciency compared to static control conditions was reported,
and a strong impact of the vessel type on EB size and agglomeration
tendency was observed. The system was improved via the imple-
mentation of a perfusion system combined with a dialysis chamber,
leading to improved culture homogeneity and process control [51].
Although RWBs provoke low shear stresses on cells/aggregates,
the limited volume capability and the complexity of the technical
solutions adopted for the horizontal rotation of the reactor vessel
impede systems’ scalability, thereby limiting their universal use for
large-scale hPSC production [24,50].
3.2. Stirred tank bioreactors
Stirred tank bioreactors (STBRs) are widely used in the biophar-
maceutical industry for the large-scale production of recombinant
proteins from common mammalian cell lines such as Chinese ham-
ster ovary (CHO) or baby hamster kidney ﬁbroblasts (BHK) cells
[21]. STBRs typically consist of a permanent glass or single-use
plastic vessel equipped with an internal impeller. In addition to
efﬁcient mixing, the impeller induces the desired uplift-current
against gravity, thereby keeping cells, cell-aggregates, and poten-
tial microcarriers in suspension [31,39,52].
Integrated probes allow for the precise assessment of the cul-
ture environment, including pH, temperature, and DO.  STBRs are
also compatible with non-destructive cell- and medium-sampling
via system-integrated ports without process interruption. Addi-
tional process monitoring and control parameters include the vital
cell density assessment (e.g., via bioreactor-integrated probes for
impedance measurement or external analyzers) and the analysis of
metabolites such as glucose, lactate, and ammonia concentrations
measured by external analyzers [22,39]. Finally, STBR technology
enables relatively linear and straightforward process up-scaling
(using stepwise increments in reactor vessel dimensions) [18,25]
and supports the ﬂexible, automated modulation of operation
modes [18], thus providing substantial new options for hPSC pro-
cess modulation and improvement further outlined below.
Generally, to enable the transition of conventional 2D-
dependent hPSC cultivation into STBRs in 3D, two  alternative
technologies have been applied. One approach relies on cell immo-
bilization on microcarriers [53–55], while the other approach of
matrix-free cell-only aggregation has been explored by us and other
researchers [44,56,57]. By using both technologies, major progress
was made in hPSC cultivation in STBRs in the recent years as out-
lined in Table 1; these achievements and the remaining challenges
are discussed in the following sections.
3.2.1. Proof-of-concept studies for hPSC cultivation in suspension
culture
While the successful propagation of human PSCs passaged as
semi-dissociated cell clumps on coated microcarriers was reported
[53–55] in parallel to respective studies with mouse PSCs [58,59],
the expansion of hPSCs as self-assembling aggregates was  initially
hindered by human PSCs’ sensitivity to rigorous dissociation into
single cells, in contrast to their less sensitive mouse counterparts
[60,61]. However, following the ﬁnding that the small molecule
Y27632 (a Rho-associated coiled-coil kinase (ROCK) inhibitor) tem-
porarily permits survival of single cell-dissociated hESCs [62], we
and other researchers showed the robust multipassage expan-
sion of undifferentiated hPSCs rigorously propagated as single
cells in suspension [44,56,57]. In addition to Y27632 supple-
mentation, it was demonstrated that hPSCs’ re-aggregation into
matrix-independent aggregates in suspension culture also depends
on other parameters, particularly on the culture medium and the
applied inoculation density [44,56,57]. Following the successful
expansion of hPSCs in stirred spinner ﬂasks (a simple STBR platform
with limited monitoring/control abilities) in 2010 [63], continu-
ous modiﬁcation and improvement of distinct process aspects were
published (Table 1).
3.2.2. Process control by controlling hPSC aggregation
The mechanical and hydrodynamic conditions in STBRs are
important for keeping cells homogenously suspended and to avoid
excessive agglomeration of aggregates but without hydrodynamic-
induced damage of PSCs [64]. Therefore, for controlling aggregate
formation and their further growth, the ﬁrst parameters that were
optimized in STBR included the impeller design, the stirring speed,
and the hPSC inoculation density.
A key aim of these studies was to ensure overall aggregate
homogeneity. In particular, the formation of extensive aggregate
dimensions must be avoided since diameter exceeding ∼300 m is
known to result in cell necrosis due to the limited nutrient and gas
diffusion into the tissue/aggregate center [64]. Eventually, uncon-
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Table 1
Overview of studies optimizing expansion of hPSCs in suspension in bioreactor vessels. The studies are sorted according to their date of publication.
Cell Type Bioreactor Type Working volume Culture System Culture media Operation mode Parameter optimized Max. cell
density
[cells/mL]
Max. cell Yield
[cells]
Peak in cell
density [day]
Refs.
hESCs  Rotating wall
bioreactor
55 mL  Embryoid bodies FCS containing
medium
Repeated batch Rotate speed.
inoculation density
36 × 106 19.8 × 108 28 [50]
hESCs Rotating wall
bioreactor
55 mL Embryoid bodies hESC KO-medium Perfusion Feeding strategy,
medium dialysis
ND ND ND [51]
hESCs Spinner ﬂask 50 mL Microcarrier MEF-CM Repeated batch Microcarrier coating 3.5 × 106 1.75 × 108 5 [54]
hESCs Spinner ﬂask, Stirred
tank bioreactor
100 mL,  300 mL Microcarrier hESC KO-medium Repeated batch
(semi continuous)
Feeding strategy, DO 1.22 × 106,  2.26
x 106
1.22 × 108,
6.78 × 108
11, 10 [55]
hESCs Spinner ﬂask 100 mL  Aggregates mTeSR1 Repeated batch Rapamycin and RI
addition
0.45 × 106 0.45 × 108 6 [63]
hESCs Spinner ﬂask 50 mL  Aggregates KO-SR medium,
mTeSR1
Repeated batch Medium, stirring
speed, heat shock
treatment
2.4 × 106 1.2 × 108 7 [45]
hiPSCs Stirred tank bioreactor 100 mL  Aggregates mTeSR1 Repeated batch Impeller design,
stirring speed,
inoculation density
2.0 × 106 2.0 × 108 7 [65]
hESCs Spinner ﬂask* 60 mL  Aggregates mTeSR1, StemPro hESC
SFM
Repeated batch Medium, inoculation
density
1 × 106 0.60 × 108 3 [66]
hiPSCs, hESCs Spinner ﬂask 100 mL  Aggregates HFF-CM Repeated batch Medium, dissociation,
stirring speed,
inoculation density, DO
1.4 × 106 1.4 × 108 10 [77]
hiPSCs Spinner ﬂask 45 mL  Aggregates E8 Repeated batch Medium ∼1.7 × 106 0.77 × 108 5 [78]
hiPSCs, hESCs Spinner ﬂask 50 mL  Microcarrier mTeSR1 Repeated batch Feeding strategy 6.1 × 106 3.05 × 108 7 [72]
hESCs Spinner ﬂask 60 mL  Microcarrier KSR medium, KSR-XF,
BRASTEM
Repeated batch Medium 2.78 × 106 1.67 × 108 6 [92]
hESCs Spinner ﬂask 100 mL  Aggregates mTeSR1 Batch Stirring, inoculation
density
(32-factorial)
0.24 × 106 0.24 × 108 6 [74]
hESCs Spinner ﬂask 60 mL  Microcarrier Not exactly stated Repeated batch Microcarrier type and
coating
2.07 × 106 1.24 × 108 10 [76]
hiPSCs Spinner ﬂask 50 mL  Microcarrier E8 Repeated batch Carrier-coating,
inoculation density,
stirring (32-factorial)
1.4 × 106 0.7 × 108 10 [75]
hiPSCs Stirred tank bioreactor 100 mL  Aggregates mTeSR1, E8 Perfusion Feeding strategy,
Medium (xeno-free,
fully deﬁned)
3.01 × 106 3.01 × 108 7 [85]
Abbreviations: MEF: Mouse embryonic ﬁbroblasts; CM: Conditioned medium; KO: Knock-out; RI: ROCK inhibitor (Y-27623); KO-SR: Knock-out serum replacement; SFM: Serum-free medium; HFF: Human foreskin ﬁbroblasts;
KO-SR:  Knock-out serum replacement; XF: xeno-free.
* Authors state transition into 500 mL  spinner ﬂasks; however, no details on the working volume or cell densities, etc.,  are given.
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trolled differentiation – particularly in large hPSC aggregates –
might also occur. The regular dissociation of aggregates into single
cells at every passage is therefore an integral part of the estab-
lished suspension culture strategy; this contradicts uncontrolled
hPSC differentiation and supports sustained culture homogeneity
and quality [45].
In the ﬁrst published trials of hPSC expansion in STBRs, relative
high cell densities of ∼2–3.5 × 106 cells/mL were readily achieved
[54,65]. The robustness of both microcarrier- and aggregate-based
hPSC expansion processes was underlined, and maintenance of
pluripotency and karyotypic stability over several passages was
conﬁrmed [54,66].
However, in STBRs both the direct interaction of the cells
with the vessel components and the complex hydrodynamic con-
ditions may  induce critical stresses. In particular, the geometry
and the position of the impeller in combination with the agi-
tation rate and the position of analytical probes can lead to
complex, spatially and temporally modulated ﬂuid shear stresses
and heterogeneous mass transport, resulting in localized areas of
turbulence and subsequently detrimental stresses [24,67]. Such
non-physiological environment may  change receptor-ligand bind-
ing properties, thereby affecting cells’ metabolism and phenotype
[47], reducing the viability [57,65,68], and disrupting the sensi-
tive equilibrium of pluripotency versus differentiation, eventually
inducing undesired culture heterogeneity [18,57]. Effects of shear
stress on pluripotency and differentiation properties have been
described for mouse pluripotent stem cells [69–71]. Furthermore,
differentiation induction has been observed in microcarrier-based
hPSCs cultures due to inappropriate culture agitation [72].
For these reasons, the optimization of the agitation speed and
the impeller type in combination with the inoculation density are
crucial settings for controlling aggregate size and development
[65]. In this context, several works based on experimental and
computational ﬂuid dynamics techniques have been performed
for characterizing and optimizing the 3D ﬂuid dynamics in STBRs
[73–77]. Consequently, modulations of bioreactor designs have
been proposed [65,78–80]. Nevertheless, the inﬂuence on stem
cell expansion and pluripotency of mechanical and hydrodynamic
conditions arising from complex combination of factors – such
as impeller/vessel geometries and imposed rotating conditions –
remains challenging to be assessed, in particular because of the
interplay of the complex mechanical and biological properties of
the system [64,67]. Moreover, as the shear stress at the impeller tip
increases with the bioreactor scale [47], the investigation of these
hydrodynamic aspects will become even more important when
hPSC expansion will be scaled-up beyond current dimensions of
100–300 mL  (Table 1) toward 1–2 L scale (as recently published
[40]) and subsequently towards dimensions of 10–1000 L envi-
sioned for the “off-the-shelf” therapeutic cell production in future
[16,18,48].
3.2.3. Process control by operation modes
Recently, work on hPSC expansion in STBRs aimed at more
sophisticated operation modes to test the impact of alternative
feeding strategies [55,81]. Most upstream stem cell culture pro-
cesses can be categorized into the following four operation modes:
batch, repeated batch, fed batch, and continuous feeding with cell
retention, the later also known as perfusion [82] (Fig. 3A–D).
3.2.3.1. Batch. In batch mode (discontinuous processes), nutrients
are provided only at process initiation (Fig. 3A). No subsequent sup-
plementation is performed after process inoculation besides the
addition of acid or base, anti-foam detergents, or the modulation of
gassing, as required. Thus, batch is the simplest operation mode,
entailing the lowest risk for contamination. However, modest
cell yields are expected given by the limited nutrient concen-
trations that are tolerated by most cell types before inducing
detrimental effects by hyperosmosis [82]. Since PSCs depend on
the regular (nearly daily) supply of growth factors (that is bFGF
and TGFß for human PSCs and LIF for mouse PSCs) to maintain
stemness [49], strict batch processing is essentially incompatible
for prolonged stem cell expansion. Batch processes, however, were
described for hPSC cultures inoculated at very low cell densities
of 2–8 × 104 cells/mL, which seems to be compatible with mod-
est nutrient supply [83], but is inappropriate for the production of
relevant cell numbers for most applications.
3.2.3.2. Repeated batch. For achieving higher cell yields, repetitive,
more advanced processing strategies have been established. In the
ﬁeld of stem cell bioprocessing, the term “repeated batch” (some-
times also called “semi-continuous”, e.g., in [55]) is often used to
describe a process that is initiated with a batch phase (typically
lasting for 48 h), followed by repeated feeding cycles without cell
harvest (Fig. 3B). This operation mode, which is also typical for
the conventional PSC cultivation in 2D in a dish, was  successfully
applied by several groups using both microcarrier- [54,55,81,84,85]
and aggregate-based suspension culture [45,63,65,66,80,86]. Thus,
this is the most used feeding strategy for hPSC expansion to date.
It is worth to highlight that some groups including us have applied
very short cycles of repeated batch feeding, i.e.,  performing partial
medium replacement after every ∼2 h culture interval, to achieve
“perfusion-like” conditions termed “cyclic perfusion” [42,55].
3.2.3.3. Fed batch. In fed batch processes, in contrast to batch culti-
vations, one or more nutrients – usually glucose and amino acids –
are supplemented by a concentrated feed stream during the culti-
vation, resulting in an increased culture volume over time (Fig. 3C).
This nutrient replacement enables to achieve higher cell densities
than that in batch cultures [82]. Although fed batch processes have
been successfully applied for hematopoietic stem cell expansion
[87], to our knowledge, no studies have used this strategy for hPSC
cultivation. The method applicability might be hindered not only
by the accumulation of toxic metabolites but also by the limited
stability of growth factors mandatory for maintaining pluripotency
[88].
3.2.3.4. Perfusion. Perfusion is characterized by the continuous
replacement of medium from the reactor by fresh medium while
retaining cells in the vessel by speciﬁc systems (Fig. 3D). Perfusion
is often described as the superior operation mode for biophar-
maceutical production processes enabling highest cell densities
and productivity. However, perfusion feeding also represents the
highest level of operational complexity, medium costs, and con-
tamination risk [82]. Beside the advantage that cells in perfusion
are constantly provided with fresh nutrients and growth factors,
potentially toxic waste products are washed out, ensuring more
homogeneous conditions in the reactor. Moreover, compared to
repeated batch processes, perfusion processes support process
automation and improved feedback control of the culture environ-
ment, including DO, pH, and nutrient concentrations [82]. Perfusion
cultures may  be optimized toward a relatively stable, physiolog-
ical environment that also supports the self-conditioning ability
of hPSCs by their endogenous factor secretion and thus eventu-
ally reducing supplementation of expensive medium components
[88,89].
Lastly, in contrast to repeated batch cultures, which currently
require manual withdrawal/replenishment of medium, no process
interruption is mandatory in perfusion processes, thus minimizing
operational errors [82].
Despite these advantages, only few studies have been published
on the application of perfusion for PSC cultivation. By using a per-
fusion system based on matrix-attached monolayer culture, early
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Fig. 3. Bioreactor operation modes. As feeding strategies in hPSC expansion, the following bioreactor operation modes can be adopted: (A) Batch – nutrients are provided
only  at process initiation. No subsequent feeding is performed afterwards and the working volume V remains constant; (B) Repeated batch – in this semi-discontinuous
mode,  after an initial batch phase, part of the medium is cyclically refeed with fresh medium without harvesting the cells, and the working volume V, except during the
medium replacement passages, remains constant; (C) Fed batch – after an initial batch phase, during the cultivation the cells are supplied with fresh nutrients (normally via
a  concentrated feed medium) via the feed steam. Since the medium is not removed, this results in an increased working volume V over time; (D) Perfusion – after an initial
batch  phase, fresh medium is continuously added to the culture, while spent medium is continuously removed at the same ﬂow rate; thus, the working volume V is kept
constant. The cells are maintained inside the bioreactor via an internal or an external cell retention system. For each mode, the evolution in time of the medium feeding
(graphs  F-t) and of the working volume (graphs V-t) is provided. Figure adapted from [82,88].
work on human ESC suggested the supportive effect of perfusion
[90]. This was conﬁrmed for mouse PSCs expanded in STBRs in
suspension cultures on microcarrier using ultrasonic separation or
gravimetric control for cell retention [91,92] and for mouse PSCs
grown as aggregates [60,92]. For human PSCs, cyclic perfusion-like
conditions have been established using microcarrier and gravimet-
ric control for cell retention [55]. Moreover, perfusion has been
established using hPSC aggregate culture with a ﬁltration system
for cell retention more recently [93].
In the latter study, it was shown that perfusion resulted in
much more homogeneous culture conditions and avoided zig-
zag-like patterns of the main process parameters such as pH and
DO, typical of repeated batch processes. In consequence, perfu-
sion enabled signiﬁcantly higher cell densities of ∼3 × 106 cells/mL
on average using the same medium throughput (i.e., 1x process
volume/day) and process duration (7 days), thereby outperform-
ing repeated batch controls by 50% with regard to the average
cell density of 2 × 106 cells/mL and the respective overall cell yield
[93] (Fig. 4A–C). Interestingly, investigations on hPSC physiology
and global gene expression patterns revealed distinct changes in
the cells’ energy metabolism in a time-dependent manner in both
repeated batch and perfusion processes [93]. The study suggests
a suspension culture-induced switch from glycolysis to oxidative
phosphorylation but notably in the absence of hPSC differenti-
ation. This highlights the plasticity of hPSC energy metabolism
and provides novel physiological and molecular targets for process
monitoring and further optimization.
3.2.4. Control of speciﬁc process parameters
First attempts on controlling pH and DO in stem cell bioprocess-
ing have been reported. For controlling pH, only a limited number
of studies have been reported so far for mouse PSCs [68,94].
More but also quite controversial studies have been published
on the impact of oxygen modulation. As oxygen solubility in aque-
ous solution is relatively low, i.e.,  the saturation concentration is
∼7 mg/L at 37 ◦C, continuous oxygen supply is necessary to ensure
a stable concentration throughout the expansion processes of fast-
proliferating cells [82]. However, to limit the excessive formation of
free radicals, DO levels of 20% to 50% of air saturation are commonly
used in mammalian cell cultures [82,95].
In uncontrolled 2D systems, a beneﬁcial effect of hypoxia
(deﬁned by ∼2–5% DO in respective studies) on hPSC expansion and
pluripotency has been reported [96–98]. However, in these studies,
the gas composition was  modiﬁed without monitoring or control-
ling the dissolved oxygen tension resulting in the culture. This, to
our experience, strongly differs from the gassing conditions. These
studies are therefore difﬁcult to interpret and results might be mis-
leading, as also suggested by the work of Serra et al. [55]. By using
a controllable bioreactor system, this study reported three times
higher cell densities when DO was controlled at 30% compared to
5% air saturation. However, more studies using DO-control based
on online DO-monitoring might be required in order to conclude
about optimal DO set points for hPSC expansion.
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Fig. 4. Comparison between repeated batch and perfusion operation modes for inﬂuence on hPSC expansion. (A) Comparison of growth kinetics during repeated batch and
perfusion operation modes culturing hCBiPS2 cells for 7 days in a stirred tank bioreactor. Cells were seeded at 0.5 × 106 cells/mL on d0. During the ﬁrst 48 h, cultures were
maintained without any medium exchange. From day 2, in repeated batch culture, the entire medium was replaced daily, while in perfusion culture, the perfusion was
initiated (4.2 mL/h), keeping the daily and overall medium throughput equal for both feeding strategies. Up to 4.6-fold increase in repeated batch culture and up to 6.7-fold
increase in perfusion culture could be achieved. (B) Glucose concentration patterns in the repeated batch and perfusion cultures of hCBiPS2 cells for 7 days in the stirred
tank  bioreactor. (C) Impact of feeding strategies on aggregate formation and size distribution. hCBiPS2 were detached from monolayer cultures and injected as single cell
suspensions on day 0 within the stirred tank bioreactor. At day 7, the cells from both processes were harvested and analyzed. On process days 1, 2 (before the ﬁrst repeated
batch  medium change and perfusion start), and days 3–7, the morphological features of the aggregates were assessed by light microscopy, as exemplary shown (scale bars:
200  m).  Figure adapted from [93].
3.2.5. Progress towards cGMP-compliance
Aiming at clinically compliant hPSC processing, substantial
progress was made in recent years. This includes the use of xeno-
free and chemically deﬁned culture media, cGMP-compliant cell
banking, and the use of cGMP-compliant single-use bioreactors.
In 2011, Chen et al. reported “essential 8” (E8), a xeno-free and
completely deﬁned culture medium, for hPSC cultivation [99]. This
medium was shown to support hPSC maintenance in an aggregate-
based suspension culture [80,93] and xeno-free microcarrier-based
cultivation in STBRs [84]. Further, xeno-free culture media were
successfully used in hPSC suspension culture systems, including
BRASTEM [100] and the StemMACSTM iPS-Brew XF (unpublished
data by our group).
Aiming at establishing cGMP-compliant strategies for hESC cell
banking, Chen and coworkers developed a promising method to
generate cell banks of several hESC lines [66]. In this study, sus-
pension culture using serum-free and deﬁned media for hESC
expansion in spinner ﬂasks was used, and feasibility for mass
hESC production further supporting future clinical translation was
demonstrated. hESCs were passaged for at least 20 times whereby
>1 × 1013 fold expansion of the inoculated cells was (theoreti-
cally) calculated and pluripotency and a normal karyotype were
maintained. Furthermore, the cells harvested from this system
were cryopreserved in serum-free medium and thawed into either
adherent or suspension culture to continue passaging and expan-
sion, providing a GLP- and cGMP-compliant method for generating
hESC banks [66].
Finally, successful translation of an expansion process into
single-use stirred tank bioreactor was shown by us [93], represent-
ing another important step toward clinical applications. Whereas
STBRs made of stainless steel or glass require cost-intensive and
elaborated cleaning and validation procedures at every process
cycle, fully instrumented single-use stirred tank bioreactors, which
have been developed from 100 mL  to 1000 L scale, overcome these
time- and cost-consuming procedures [22,31,101]. Single-use cul-
ture vessels are therefore of great interest for the envisioned
clinical translation of hPSCs as they support the development of
GMP-compliant upstream processes with reduced risk of cross-
contaminations and increased product safety [2,102].
4. Final remarks and outlook
Published studies discussed in this paper clearly indicate that
suspension culture of hPSCs in stirred tank bioreactors is a promis-
ing approach for generating relevant cell numbers under more
controlled conditions. However, the ﬁeld of hPSC mass cultiva-
tion and differentiation is still at its infancy. Process scalability and
standardization are challenging tasks reﬂecting the complexity of
both pluripotent stem cell properties and large-scale cell process-
ing, particularly with respect to process standardization and quality
requirements raised by industrial and clinical translation.
Moreover, compared to conventional mammalian cell lines,
which can typically be grown in relatively homogenous suspen-
sion of single cells or small clumps, hPSCs raise substantially higher
challenges. This reﬂects the fact that the aggregate size constantly
changes throughout the entire culture process (Fig. 4) and the
potential for cell differentiation is a constant “threat.”
Regarding the successful up-scaling of hPSC production in
stirred tank bioreactors, it becomes fundamental to deﬁne the key
operational parameters that allow a direct transfer of agitation
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conditions established at the (currently relative low) optimization
scale toward an increasing process scale.
Therefore, parameters such as the impeller type and dimension,
impeller’s location along the longitudinal reactor axis, and the agi-
tation speed – all in combination with the cell inoculation density –
must be considered and optimized for successful translation from
laboratory to production scale. For example, when increasing the
bioreactor scale, impeller dimensions must also be adapted. This
results in increased shear stress at the impeller tips, which could
affect cell viability and pluripotency. Therefore, an in-depth anal-
ysis of the impact of the increased impeller dimensions and the
interplay with the agitation speed is required in future.
Because of this complexity, impeller-free technologies assuring
laminar mixing ﬂow regimen at low shear stress conditions might
provide an interesting solution as recently demonstrated with a
novel bioreactor type [103].
Moreover, since the aggregate development patterns and kinet-
ics, the average (overall) aggregate size, and the degree of aggregate
homo- vs. hetero-geneity have been shown to substantially alter
lineage differentiation and process efﬁciency [43,60,61,104], novel,
process-integrated tools aiming at better control of aggregate
dimensions are urgently requested for hPSC processing.
In case of large-scale perfusion processes, large quantities of
culture medium will be required. Therefore, further media opti-
mization aiming at more cost-effective formulations will become
crucial. Substituting costly growth factors with small molecules
or more stable protein analogues may  pave the way. An alter-
native strategy may  include the implementation of a dialytic
membrane into the perfusion circuit as described by Come et al. for
RWBs [51]. The aim of this approach is to maintain hPSC-released
pluripotency- and proliferation-supporting growth factors inside
the bioreactor but, in parallel, enabling steady replacement of con-
sumed glucose and removal of toxic metabolites by the molecule
size-selective features of the membrane.
Regarding the cGMP- and regulatory-compliant hPSC produc-
tion, the Food and Drug Administration (FDA), the European
Medicines Agency (EMA), and the biopharmaceutical industry
are promoting initiatives aimed at deﬁning and implementing
“Quality by Design” (QbD) and “Process Analytical Technologies”
(PAT) approaches [101], which might have important impact on
hPSCs bioprocessing. The QbD approach aims to ensure the qual-
ity of medical products by employing statistical, analytical, and
risk-management methodology into the design, development, and
manufacturing process, as deﬁned by the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use (ICH) [105]. PAT is deﬁned by the FDA as “a system
for designing, analyzing, and controlling manufacturing through
timely measurements (i.e., during processing) of critical quality
and performance attributes of raw and in-process materials and
processes, with the goal of ensuring ﬁnal product quality” [106].
Therefore, critical sources of variability in a production process
must be known and understood; variability itself should be man-
aged by the process design and the product’s quality should be
reliably predictable [101].
For hPSC expansion the implementation of online measure-
ment and the control of process parameters such as DO, pH, vital
biomass, and nutrient/metabolites, which has only recently been
introduced to hPSC cultivation, will be fundamental [22]. This
technology could provide the missing link for allowing laboratory-
scale hPSC processes to become measurement-driven operations
[107], an indispensable step for relating process conditions to
hPSC production quality. More sophisticated tools for online pro-
cess monitoring and control, which might help implementing the
QbD and PAT requirements, are currently under development.
These technologies include automated 3D microscopy of aggre-
gates [108], label-free and noninvasive monitoring of the cell’s
pluripotency state [109], and Raman spectroscopy and NMR-based
metabolomics for the monitoring of multiple culture parameters
[110,111]. The latter has been recently applied to monitor lineage-
speciﬁc hPSC differentiation [112]. Integrated into controlled and
automated bioreactors, these nondestructive and noninvasive
measurement technologies could substantially expand the options
for hPSC monitoring, including the online observation of, e.g., hPSCs’
proliferation, differentiation, and maturation kinetics, ultimately
leading to robust hPSC production at the required standards. This
standardization, guaranteeing higher reproducibility and safety in
the hPSC production process, will boost the rapidly developing
and highly competitive cell therapy industry [113–115], moreover
enabling the attraction of capitals and investors.
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